Table 3 Treatment-emergent adverse events in patients (n = 81)

From: A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer

 

No. (%)

Grade 1 or 2

Grade 3

Grade 4

Neutropenia

32 (40%)

38 (47%)

5 (6%)

Leukopenia

57 (70%)

16 (20%)

0

Diarrhea

56(69%)

14 (17%)

0

Anemia

52 (64%)

3 (4%)

0

Oral mucositis

47 (58%)

4 (5%)

0

Nausea

26 (32%)

0

0

Rash

22 (27%)

1 (1%)

0

Hypokalemia

20 (25%)

1 (1%)

0

γ-glutamyl transferase

Increased

15 (19%)

1 (1%)

0

Fatigue

13 (16%)

1 (1%)

0

Hyponatremia

13 (16%)

0

0

Vomiting

13 (16%)

0

0

Headache

11 (14%)

0

0

Hypocalcemia

10 (12%)

0

0

Platelet count decreased

9 (11%)

0

0

Dizziness

9 (11%)

0

0

Hypercholesteremia

7 (9%)

1 (1%)

0

Alopecia

5 (6%)

0

0

Alanine aminotransferase

Increased

2 (2%)

2 (2%)

0

Aspartate aminotransferase

Increased

0

0

1 (1%)

  1. Data are presented as n (%).